BANK VONT C/WTS 21 | Market Closed - Swiss Exchange 09:50:00 26/02/2024 pm IST | ||
| 0.107 CHF | +72.58% |
|
| Current year | +72.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
More news
Static data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | 
Vontobel
|
| WIDB3V | |
| ISIN | CH1260785568 |
| Date issued | 23/05/2023 |
| Strike | 9 CHF |
| Maturity | 21/06/2024 (32 Days) |
| Parity | 4 : 1 |
| Emission price | 0.49 CHF |
| Emission volume | N/A |
| Settlement | physique |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.542 CHF |
|---|---|
| Lowest since issue | 0.022 CHF |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 0.2500 |
| Difference Strike | 6.78 CHF |
| Difference Strike % | +75.33% |
| Intrinsic value | 0.000000 |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.22
CHF
Average target price
1.724
CHF
Spread / Average Target
-22.35%
- Stock Market
- Warrants
- WIDB3V Warrant